DIVE

Completed

Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes

Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes: A Multi-center Observational Study

Lead sponsor

Shanghai Zhongshan Hospital

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

100

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoint

•Effect on glycemic variability

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04374578

Org study IDZSE-202003

Timeline

Milestones

Study first posted2020-05-05actual

Study start2020-05-08actual

Primary completion2021-01-31actual

Study completion2021-06-30actual

Last update posted2022-03-31actual

Assets

Investigational agents

Dulaglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Type 2 diabetes come to the clinic who want to use dulaglutide and never used dulaglutide before

Inclusion criteria

•Fully understand the test content and possible adverse reactions and voluntarily participate in the trial and sign the informed consent form;

•Meet the World Health Organization(WHO) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes;

•18 ≤ age ≤ 70 years old, male or female;

Exclusion criteria

•Subjects with Type 1 diabetes mellitus or secondary diabetes mellitus (i.e. any type other than T2DM)

•Personal history or family history of thyroid medullary carcinoma or multiple endocrine neoplasia type 2 (MEN2).

•History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study (e.g. due to symptomatic gallstones).

•History of significant gastrointestinal (GI) surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function.

•Fasting triglyceride level more than 750 mg/dL at screening.

•Estimated Glomerular Filtration Rate (eGFR) less than 60 mL/minute/1.73 meter^2 (calculated using the Schwartz equation) at screening.

•ALT more than 2.5x upper limit of normal (ULN) or Bilirubin more than 1.5xULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin more than 35%) at screening.

•Use of a GLP-1receptor agonist at study entry and during the study.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint/low confidence

Effect on glycemic variability

Time frame:one months

descriptive, improvement

Secondary/protocol endpoint/low confidence

Effect on Glycemic Control

Time frame:one months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.